Same (S-Adenosyl Methionine) for Liver Health

The studies provided do not directly investigate SAMe supplementation for liver health in humans. Rather, the research collected here examines related upstream topics such as one-carbon metabolism, methylation chemistry involving SAM and SAH as biomarkers, methionine and choline deficiency in animal models, and metabolic disruptions in conditions like COVID-19, malnutrition, and kidney disease. These are largely observational, mechanistic, and animal studies that touch on biochemical pathways in which SAMe participates, but none test SAMe as a therapeutic intervention for liver conditions specifically. Research suggests that disruptions in methylation and one-carbon metabolism are associated with liver and metabolic dysfunction in various disease states, which is consistent with the broader scientific rationale sometimes cited for SAMe in liver health contexts, but the studies provided here do not offer direct clinical evidence supporting or refuting SAMe supplementation for this purpose. Readers seeking evidence on SAMe and liver health specifically should look to dedicated clinical trials and meta-analyses examining conditions such as alcoholic liver disease, nonalcoholic fatty liver disease, or intrahepatic cholestasis, which fall outside the scope of what this particular set of studies addresses.